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Probiotics have a range of proposed health beneﬁts for the consumer, which may include modulating the levels of beneﬁcial
elements in the microbiota. Recent investigations using molecular approaches have revealed a human intestinal microbiota
comprising over 1000 phylotypes. Mechanisms whereby probiotics impact on the intestinal microbiota include competition
for substrates, direct antagonism by inhibitory substances, competitive exclusion, and potentially host-mediated eﬀects such as
improved barrier function and altered immune response. We now have the microbial inventories and genetic blueprints to begin
tackling intestinal microbial ecology at an unprecedented level of detail, aided by the understanding that dietary components
may be utilized diﬀerentially by individual phylotypes. Controlled intervention studies in humans, utilizing latest molecular
technologies, are required to consolidate evidence for bacterial species that impact on the microbiota. Mechanistic insights should
be provided by metabolomics and other analytical techniques for small molecules. Rigorous characterization of interactions
between the diet, microbiota, and probiotic bacteria will provide new opportunities for modulating the microbiota towards
improving human health.
Copyright © 2008 P. W. O’Toole and J. C. Cooney. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTORY REMARKS
The history of microbiological research has been dominated
by investigations of the agents of human infectious disease.
Motivated by the desire to culture, characterize, and under-
stand the pathogenicity mechanisms of these organisms,
several centuries of microbiological research culminated in
a broad range of antimicrobial therapies, vaccines, and
immunizations. In more recent years, similar analytical
methodologies have been applied to facilitate exploitation of
bacteria for industrial applications. Two related branches of
microbiology—environmental microbiology, and the study
of intestinal commensals (a branch of the ﬁrst in purest
terms)—lagged behind until relatively recently. From the
mid 1990s, a range of techniques allowed environmental
microbiologists to indentify soil microorganisms in situ,
without resorting to culture, based upon ribosomal small
subunit RNA gene probes. A natural extension of this
approachwastosequencelargenumbersofclonedribosomal
RNA gene amplicons, yielding catalogs of all the organisms
(the microbiota) present in complex samples. Latterly the
ﬁeld of metagenomics has provided technical approaches
to sequence large fractions of the entire microbial DNA
presentinanecologicalsystem.Coupledwiththeapplication
of molecular tools for studying commensal bacteria, many
of which were originally developed for studying pathogens,
there is now an exciting nexus between technologies and
research foci whereby commensal bacteria may be studied
in the context of intestinal ecosystems. This review will
summarize what is known about the eﬀect of introduc-
ing probiotic bacteria on the composition and activities
of the microbiota, with an emphasis on recent studies
using culture-independent methods. The likely mechanisms
whereby commensals exert their inﬂuence are discussed, and
directions for future research are outlined.
2. THE CONCEPTS OF PROBIOTICS AND PREBIOTICS
The notion that certain intestinal microorganisms might
beneﬁt the host derives historically from suggestions by
Metchnikoﬀ and others that putrefying bacteria that con-
tribute to toxiﬁcation and aging could be deliberately2 Interdisciplinary Perspectives on Infectious Diseases
Table 1: Beneﬁcial properties reported for probiotic bacteria.
Host beneﬁt Microbial trait implicated Reference1
Immune modulation
Stimulation of immunity Enhance T-cell numbers and activity levels [13]
Dampening of inﬂammation Promote anti-inﬂammatory cytokine production [14]
Pathogen burden reduction
Competitive exclusion [15]
Direct antagonism [16, 17]
Uncharacterised [18, 19]
Improved gut barrier function Promote gut barrier integrity [20]
Reduced cancer risk Detoxiﬁcation of carcinogenic metabolites [21]
Reduced atopic allergy symptoms Suppression of hypersensitivity [22]
Reduced cardiovascular disease risk Cholesterol reduction by deconjugation of bile salts [23, 24]
Production of anti-hypertensive peptides [25]
Alleviation of dietary intolerance Catabolism of dietary ingredients [26]
Enhanced nutrient value Vitamin and co-factor production [27]
Alleviation of IBS2 symptoms Not deﬁned [28, 29]
1Sample reference for each trait. See main text for review references,
2Irritable bowel syndrome.
replaced by fermentative organisms [1, 2]. In this context,
some of the fermentative bacteria, Metchnikoﬀ was referring
to, are what we now consider as probiotic. Probiotic
bacteria are live microorganisms which when administered
in adequate amount confer a health beneﬁt on the host
[3, 4]. Many microorganisms that are considered probiotic
have been traditionally used to preserve food products
by fermentation, and are present in the food in varying
numbers, along with their fermentation end products and
other metabolites. Thus another operational deﬁnition of
the term probiotic requires the organism in question to be
“consumed in adequate amounts” to confer a beneﬁt [5].
The host beneﬁts that have been attributed to consumption
of probiotic microorganisms are diverse (reviewed in [3, 6–
8]; some major examples are listed in Table 1), and have
been substantiated to diﬀerent degrees. Probiotic bacteria
are now included in a wide range of consumer formulations
including yoghurts, drinks, capsules, and dietary supple-
ments, and they represent a signiﬁcant element in the mod-
ern functional foods market. Organisms used as probiotic
agents are frequently members of the genera Lactobacillus
or Biﬁdobacterium,b u tEscherichia coli, Bacillus subtilis,
Saccharomyces boulardii, and Enterococcus faecium are also
employed, among others [9]. Thus, an organism employed
as a probiotic agent may not necessarily be part of what is
considered the “normal microbiota.” Tannock distinguishes
between allochthonous and autochthonous species [10, 11].
Autochthonous means bacteria both present and replicating
in situ in the human GI tract, as distinct from transiently
passing through (allochthonous). Bacteria administered as
probiotic agents are not necessarily autochthonous to the
consuming animal, and indeed some Lactobacillus species
may only be autochthonous for certain human individual
subjects, and possibly not the majority of subjects (see
below). Rate of growth of allochthonous lactobacilli may be
a critically limiting step preventing their establishment [12].
With regard to developing probiotic strains for exploitation,
it may prove easier to identify beneﬁcial traits in species that
are autochthonous to the human consumer, as consumer
acceptanceislikelytobeeasieriftheprobioticingredientina
functionalfood(afoodproductwithbeneﬁttotheconsumer
over and above inherent nutrition) was ﬁrst cultured from
humans.
Related to the consumption of probiotic agents is the
notion of dietary adjustment to stimulate bacterial growth.
A prebiotic compound is deﬁned as “a nondigestible food
ingredient that beneﬁcially aﬀects the host by selectively
stimulating the growth and/or activity of one or a limited
number of bacteria in the colon and thus improves host
health”[30,31].Itfollowsfromthisdeﬁnitionthatthebacte-
ria capable of metabolizing prebiotics should be restricted to
a small number of beneﬁcial species or strains (reviewed in
[32]). In practice, prebiotic compounds must also be refrac-
tory to host digestive processes, and the combined catabolic
activities of bacteria higher up in the gastrointestinal tract,
so that prebiotic compounds are often oligosaccharides
towards which probiotic bacteria produce speciﬁc hydrolases
[33]. Prebiotics are commonly found in, or extracted from,
plant material including fruits, cereal, and vegetables, but
are also present in human milk and colostrum [6]. The
best characterized prebiotics include inulin, fructooligosac-
charide, galactooligosaccharide, xylooligosaccharide, isoma-
ltooligosaccharide, and lactulose (reviewed in [32]). Unrav-
elling the health beneﬁts of prebiotics is a challenging task,
because these compounds have parallel direct eﬀects on the
host,andpotentiallyonmultiplemembersofthemicrobiota.
Forexample,β-glucansareunbranchedpolysaccharideswith
(1-4) and (1-3)-linked β-D glucopyranosyl units, that are
recognized as important dietary ingredients (reviewed in
[34]). β-glucans are components of plant cell walls, and are
abundant in the endosperm of cereals such as barley and
oatmeal. Consumption of β-glucans has attendant healthP. W. O’Toole and J. C. Cooney 3
beneﬁts that are recognized by health and regulatory bodies
in several jurisdictions including the US [35]. These beneﬁts
include lowering of blood cholesterol and lipoprotein [36],
lowering of postprandial glucose and insulin responses [37],
and enhancement of antitumor monoclonal antibodies [38].
Supplementation of mammalian diet with β-glucan, or
modiﬁcation by prehydrolysis of in vitro bacterial growth
medium, leads to increased numbers and proportions of
lactobacilli or biﬁdobacteria [39–41]. Furthermore, β-gluco-
oligomers promoted the growth of L. rhamnosus GG [40].
Barley supplementation of rat diet [39] led to an increase
in Lactobacillus numbers, a decrease in Bacteroides and
coliforms, and an increase in the production of butyrate.
Butyrate is an important energy source, signalling metabo-
lite, proliferation stimulus for normal colonic epithelial
cells, and anti-proliferative signal for neoplastic colonocytes
[42, 43], suggesting a potential direct beneﬁt from dietary
ingredients or prebiotics that promote growth of clostridia.
3. THE NORMAL MICROBIOTA OF
HUMANS AND ANIMALS
Until recently, the composition of the microbiota was
examined by relatively insensitive techniques. Culturing the
bacteria was unrepresentative, because a large proportion
of the bacteria do not grow on standard laboratory media
[44]. Analysis by temperature gradient gel electrophoresis
provided one of the earliest insights into the uncharted com-
plexity of the microbiota [45]. Using denaturing gradient
gel electrophoresis (DGGE) of 16S rRNA gene amplicons,
the same group later showed that the colonic mucosal
microbiota and faecal microbiota were diﬀerent, and the
colonic mucosal microbiota was likely dependent on host
factors [46]. Meanwhile ﬂuorescent hybridization of probes
for 16S rRNA genes was being applied to determine species
identities, numbers, and proportions of intestinal bacteria
[47, 48], exempliﬁed by the studies of Dore, Blaut and col-
leagues [49, 50]. These analyses highlighted extensive inter-
individual variation at phylotypes level (among northern
Europeans) [49], and some correlations of microbiota with
age, gender, and geographic origin but which varied between
countries [50].
Our current understanding of the intestinal microbiota
(reviewed in [51, 52]) has been signiﬁcantly shaped by
culture-independent methods, in particular the sequencing
of 16S rRNA gene amplicons, either from clone libraries
or direct pyrosequencing of the PCR product. A consensus
appears to be emerging in the literature of somewhere
between 800 and 1000 bacterial phylotypes being present in
the healthy human intestine [52]; the evidence for which will
be selectively presented here. A relatively small-scale inves-
tigation by Benno and colleagues in 2003 revealed an unex-
pectedly high number of novel phylotypes in 240 partially
sequenced 16S rRNA gene amplicons clones derived from six
elderly individuals [53]. In a pioneering study, Relman and
colleagues applied the 16S rRNA molecular inventory-based
approach, at a much larger scale than previously published,
onsamplesfrombothcolonicsitesandfaeces[54];strikingly,
the majority of the sequences derived corresponded to
uncultivated species and novel microorganisms. The human
stomach, previously considered sterile except for infections
with Helicobacter pylori, was revealed by 16S rRNA gene
library sequencing to be well populated by bacteria, based
on detection of 128 bacterial phylotypes from 23 gastric
endoscopy samples [55]. Gill and colleagues [56] sequenced
not just 16S rRNA genes, but also randomly cloned bacterial
DNA—so-called metagenomics, a concept developed for
environmental community analysis [57]. Gill et al. showed
by this metagenomic approach that the bacteria in the gut
signiﬁcantly expand the metabolic capabilities of the human
gut [56]. By generating two to three 454 pyrosequencing
runs per mouse cecum, Gordon and colleagues showed
the existence of an obesity-associated gut microbiome with
increased capacity for energy harvest [58]. Signiﬁcantly, this
balance of the microbiota was borne out when investigating
obese humans [59], showing a seminal link between human
obesity and changes in the microbiota. Furthermore, the
complexity of the microbiota in humans and 59 other
mammalian species was shown to be linked to phylogeny
(of the mammal) and the composition of the diet [60].
Analysis of the metabolic capability likely conferred by the
microbial metagenome recently revealed 237 gene families
commonly enriched in adult-type and 136 families in infant-
type microbiomes [61]. Thus, any consideration of the eﬀect
ofprobioticsontheintestinalmetagenomeshouldultimately
include analysis of the downstream eﬀects upon the host of
impacting on this metabolic capability. A more fundamental
consideration is that the genera whose members are among
the most commonly employed probiotics—Biﬁdobacterium
and Lactobacillus—are not present in the human gastrointes-
tineatthehighlevelstraditionallyexpectedbasedonculture-
based approaches, being represented by 20 phylotypes (ca.
2%) and 36 phylotypes (ca. 3.6%), respectively [52]. Thus
if probiotic bacteria impart health beneﬁts to the host
under “natural conditions,” that is, in individuals who have
normal nonmanipulated numbers of probiotic bacteria, they
accomplish this despite being at much lower numbers than
are achieved by consumption of probiotic products.
4. PROBIOTICS AND THEIR EFFECT
UPON THE MICROBIOTA
There have been relatively few studies which have rigor-
ously characterized the eﬀect upon the whole microbiota
of administering probiotic cultures, and until recently, all
such studies applied targeted analysis of speciﬁc groups
of bacteria. In one of the earliest investigations, Tannock
and colleagues observed transient and modest ﬂuctuations
in lactobacillus and biﬁdobacterium numbers following
consumption of a probiotic L. rhamnosus strain DR20 [62].
Lactobacilli and enterococci were detected more frequently
(among 10 subjects) and in higher numbers during con-
sumption. Interestingly, the presence of stable populations
of lactobacilli before the administration period precluded
long-term colonization by the administered probiotic strain
[62]. Most subjects ceased shedding the probiotic strain
in faeces soon after its consumption stopped, but the L.
rhamnosusstrainremaineddetectableinfaecesofonesubject4 Interdisciplinary Perspectives on Infectious Diseases
over 2 months after the test period. These data suggest
inter-host variables such as bacterium-host or bacterium-
diet interactions.
Probiotics and prebiotics are commonly applied in
companion animals and production animals [63, 64], and
there have been some studies of eﬀects upon the micro-
biota. Administration of a cocktail containing lactobacilli,
biﬁdobacteria, enterococci, and pediococci improved weight
gain in broiler chickens, which was associated with an
increase in numbers of Biﬁdobacterium spp., Lactobacilli,
and Gram-positive cocci [65]. Administration of a probiotic
Enterococcus faecium strain reduced E. faecalis numbers
in the intestines of weanling piglets, but total numbers
of E. faecium remained unchanged, suggesting that the
administered strain had displaced part of a ﬁxed number
of niche sites occupied by the same species [66]. Many
investigations have been published describing the eﬀects of
probiotic bacteria on human pathogens (reviewed in [67]),
someofwhicharenormalcomponentsofproductionanimal
microbiota. Enterobacteriaceae numbers were reduced when
ac o c k t a i lo ft w oLactobacillus strains was administered to
pigs [68], and a ﬁve-strain probiotic combination reduced
Salmonella enterica serovar Typhimurium shedding in pigs
[69]. Although data from small animal models for human
probiotic strains must be interpreted with caution [70], it
was interesting to note from a recent study that adminis-
tration of L. casei and L. plantarum aﬀected the diversity of
murine intestinal lactobacilli, but not the overall bacterial
community structure [71]. There was an increase in the
number of lactobacilli related to the acidophilus complex in
the inoculated mice. These animal models provide an oppor-
tunity for determining the eﬀect of probiotic administration
on the entire microbiota but must ultimately be repeated in
humans if that species is the desired host.
Studies in humans are currently few in number, and
are often focused in nature. For example, consumption of a
commercial probiotic yoghurt reduced Clostridium diﬃcile-
related diarrhoea in hospitalized patients, but eﬀects on the
broader microbiota were not studied [18]. Alterations in
the fecal microbiota have been reported in irritable bowel
syndrome (IBS) [72, 73]. However, administration of a
multispecies probiotic supplementation which alleviated IBS
had negligible eﬀect upon the composition of microbiota as
measured by quantitative PCR with group-speciﬁc primers
[74]. However, this approach may have missed changes in
microbial composition within these groups. A follow-up
study reported stabilization of the microbiota over time [75],
which was related to amelioration of symptomatology that
was absent from the placebo control group. Alterations of
the human intestinal microbiota have also been reported
in inﬂammatory bowel disease (IBD) [76–78]. Given the
clinical impetus to ﬁnd simple non-medicinal solutions to
IBD and IBS, one can anticipate renewed vigor in studies
of probiotic bacteria as agents for microbiota modulation
in these subjects. Probiotics also appear to be eﬃcacious as
adjunct therapy for infectious diarrhea, with a recent meta-
analysis revealing reduction in risk and duration of diarrhea
[79]. Most of the 23 studies included in this analysis were
descriptive rather than investigative of the microbiological
aspects, and future determination of the eﬀects on the
microbiota wrought by probiotic intervention will be very
informative. As recently as 2006, the eﬀect of probiotic
administration in humans was still being followed by bac-
teriological culture, but as concluded by the authors of one
such study, there was a clear case for culture-independent
molecular methods to be applied instead [80]. Community
proﬁling by DGGE showed that lactulose increased the levels
of Biﬁdobacterium adolescentis in subjects consuming the
prebiotic lactulose, whereas the probiotic yeast S. boulardii
did not cause any signiﬁcant universal changes in DGGE
proﬁles [81].
5. MECHANISMS OF PROBIOTIC IMPACT ON
THE MICROBIOTA
Figure 1 shows a schematic overview of the potential mech-
anisms whereby probiotic micro-organisms might inﬂuence
the intestinal microbiota. Consumption of probiotic cultures
may modulate the microbiota or change its metabolic
properties by competition for nutritional substrates. Gordon
and colleagues have used transcriptional microarrays to
show that introducing a probiotic into the mouse gut
changes the way the endogenous microbiota metabolize the
diet [82]. When germ-free mice that had been monoas-
sociated with Bacteroides thetaiotaomicron were challenged
with Biﬁdobacterium animalis or Lactobacillus casei,b o t h
interventions caused shifts in the gene expression pattern
of the B. thetaiotaomicron genome [82]. These diﬀerentially
expressed gene sets (i.e., in response to the two probiotics)
did not overlap, emphasizing that diﬀerent probiotics elicit
diﬀerent responses. However, many of the genes in B.
thetaiotaomicron whose expression was altered by presence
of either probiotic strain were related to expansion of the
carbohydrate metabolizing capability of B. thetaiotaomicron.
Thus, one of the ways in which probiotics can impact
upon the composition of the microbiota is apparently by
competing with them for substrate availability, and by alter-
ing the dynamics of carbohydrate utilization by individual
microbiota components. This competition is probably not
restrictedtotheintestine,sincerecentevidenceindicatesthat
oral Biﬁdobacterium strains (B. adolescentis) reduce vitamin
Kconcentration,andmaythuscompetewithPorphyromonas
gingivalis in the oral cavity [83].
The application of metabolic proﬁling methods to ani-
mal models has suggested another indirect way in which
probiotic bacteria might impact on the microbiota, namely,
by production of a signiﬁcantly diﬀerent microenvironment
due to a diverse range of metabolic pathway outcomes. In
a recent study using germ-free mice colonized by human
baby microbiota and exposed to two lactobacillus strains,
Nicholson and colleagues observed microbiome modiﬁca-
tion, measured by selected culture regimes [84]. This was
accompanied by changes in cecal concentrations of short-
chainfattyacids,andmarkedchangesinfecallevelsofdiverse
metabolites including choline, acetate, ethanol, a range of
putative N-acetylated metabolites (NAMs), unconjugated
bile acids (BAs), and tauro-conjugated bile acids. While a
naturalfocusofthesestudiesistheeﬀectofthesemetabolitesP. W. O’Toole and J. C. Cooney 5
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Figure 1: Schematic diagram illustrating potential or known mechanisms whereby probiotic bacteria might impact on the microbiota.
These mechanisms include (1) competition for dietary ingredients as growth substrates, (2) bioconversion of, for example, sugars into
fermentation products with inhibitory properties, (3) production of growth substrates, for example, EPS or vitamins, for other bacteria, (4)
direct antagonism by bacteriocins, (5) competitive exclusion for binding sites, (6) improved barrier function, (7) reduction of inﬂammation,
thus altering intestinal properties for colonization and persistence within, and (8) stimulation of innate immune response (by unknown
mechanisms). IEC: epithelial cells, DC: dendritic cells, T:T-cells. For further details, see main text.
upon the host [85], it is likely that such gross changes in
metabolic proﬁle also impact upon intestinal microbiota
composition. As noted in Table 1, some probiotic bacteria
also produce vitamins [27], enhanced availability of which
may modulate the microbiota. In addition, exopolysaccha-
ride produced by probiotics including lactic acid bacteria
[86] could act as a growth substrate for selected components
of the microbiota (see Figure 1).
Probiotic bacteria probably also impact on the general
microbiota by direct antagonism. It has been shown in sev-
eral recent studies that they can modulate numbers of single
model organisms in experimental systems. For example,
probiotic L. salivarius strains inhibit the growth of H. pylori
in vitro in a strain-dependent manner [17], by mechanisms
involving lactic acid secretion, and another as yet uncharac-
terized mechanism (K. A. Ryan and P. W. O’Toole, unpub-
lished). Intestinal L. salivarius strains are distinguished by
production of a broad-spectrum bacteriocin Abp118 [87],
but this is not likely to contribute to antagonism to Gram-
negative bacteria like H. pylori.H o w e v e r ,p r o d u c t i o no f
this bacteriocin Abp118 was identiﬁed as the mechanism
whereby L. salivarius UCC118 eliminated Listeria monocy-
togenes infection in a murine model, providing the ﬁrst
deﬁnitive mechanism for anti-infective activity of a probiotic
bacterium in vivo [16]. Interestingly, both the wild-type
strain UCC118 and a bacteriocin-negative derivative were
equally able to suppress Salmonella Typhimurium infection
in the mouse model, suggesting that broader antimicrobial
eﬀects on the Gram-negative components of the microbiota
may occur. From an opposite perspective, production of a
bacteriocin-like substance by vaginal enterococci has been
linked to reduction in levels of commensal lactobacilli that
is linked to vaginosis [88]. Natural competition between
commensals and opportunistic pathogens may therefore be
mediated by mechanisms such as bacteriocin production,
that can be exploited for using probiotics to modulate the
microbiota. Competitive exclusion (see Figure 1), whereby
adherent probiotic species occlude access of members of the
microbiota to the epithelium [89, 90], represents another
way of modulating the microbiota, although strong evidence
for this occurring in vivo is lacking.
The most subtle eﬀects wrought by probiotics on the
microbiota are potentially those that operate by indirect
mechanisms involving the host. Improvement of the intesti-
nal epithelium barrier function [91] might theoretically, for
example, impact on eﬃciency of invasion of pathogens,
severity of subclinical tissue damage, and release rates
of host-derived micronutrients (see Figure 1), that could6 Interdisciplinary Perspectives on Infectious Diseases
translate into impacts on the microbiota. In an analogous
manner, pathological changes in intestinal epithelium might
also favor growth of certain members of the microbiota,
if inﬂamed or damaged epithelial cells diﬀerentially aﬀect
the microbiota. It is well established that some probiotics
can suppress inﬂammation by inhibiting proinﬂammatory
cytokine production [92–94], and although the molecular
basis for this is not currently understood for probiotics,
mechanisms and molecules have recently been identiﬁed
in commensals and pathogens [14, 95]. Reduction in gut
inﬂammation by probiotics could plausibly alter the gut
environment suﬃciently to impact on the microbiota.
Furthermore, some probiotic bacteria have been reported
to stimulate the innate immune system both in animal
models and in elderly subjects [96, 97], by an unknown
mechanism. Administration of probiotic bacteria could thus
bolster innate immune activity against transient pathogens,
or non-commensal elements in the microbiota, leading to
subtle changes in long-term overall composition. However,
more studies are required to substantiate the mechanisms in
the probiotic-host interactions, and to investigate if they do
in fact impact on the microbiota.
6. KNOWLEDGE GAPS AND CONCLUDING REMARKS
There has been a rapid recent accumulation of sequence-
basedinformationonthecompositionofthegutmicrobiota.
However, for pragmatic reasons of sample collection facility,
this is largely based on fecal analysis, and the microbiota of
the colon and small intestine will be diﬀerent from feces.
Studies of the small intestine are particularly warranted
because probiotics are proportionally more numerous there,
and may exert signiﬁcant biological activity at this site.
There is adequate information in the literature to
support the hypothesis that administration of probiotic
cultures in high doses to human subjects will impact on
the intestinal microbiota. A comprehensive intervention
study, supporting this hypothesis by deep compositional and
functional metagenomics approaches, and supplemented by
metabolomics, is not currently available (June 2008). In
this hypothetical study, mechanisms whereby changes in the
microbiota that were achieved could be inferred to a degree
by global transcriptional analysis, but deﬁnitive linkages
between bacterial gene products and eﬀects upon the
microbiota could be impossible to establish because of the
regulatory issues surrounding human trials with genetically
modiﬁed organisms. As noted above, proof of principle
may be established in animal models, but ultimately these
studies must be validated in human subjects. There remains
the intriguing question of the role, if any, of the relatively
small numbers of potentially probiotic organisms as part
of the microbiota in ostensibly healthy individuals. Do
these organisms contribute to maintenance of health—or
avoidance of disease? Is the level of candidate probiotic
organisms in the microbiota critical, and does its importance
vary with age? As noted above, there is reasonable evidence
that changes in the microbiota accompany disease states
like IBD and IBS, conditions whose prevalence increases
with aging. There are attractive hygiene-related hypotheses
suggestingthatdepletionofprobioticcommensalmicrobiota
in early life may be responsible for the dramatic rise in
diseasesinvolvingimmunedysregulation[98].Thechallenge
now is to rigorously tackle the interplay of diet, microbiota,
and host factors in tractable experiments that will elucidate
the key elements in determining outcomes of this interplay,
and allow its manipulation.
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